Skip to main content
. 2015 Sep 21;10(9):e0138520. doi: 10.1371/journal.pone.0138520

Fig 3. Prostate-specific antigen concentration and core2 β-1,6-N-acetylglucosaminyltransferase-1 expression predict extracapsular extension of prostate cancer.

Fig 3

(A) Prostate-specific antigen (PSA) concentration and (B) Core2 β-1,6-N-acetylglucosaminyltransferase-1 (GCNT1) expression levels were significantly higher in prostate cancer (PCa) patients with extracapsular extension than in patients with organ-confined disease. (C) Receiver-operator characteristic curve analysis of PSA and GCNT1 revealed that the area under the curve of PSA was 0.7455 and GCNT1 was 0.7614. (D) Risk stratification was established using PSA and GCNT1 to predict the outcome of local PCa. Double negative (DN)-risk (PSA < 7.52 ng/mL, GCNT1< 79.36 pg/mg), single positive (SP)-risk (PSA > 7.52 ng/mL or GCNT1 > 79.36 pg/mg) and double positive (DP)-risk (PSA > 7.52 ng/mL and GCNT1 > 79.36 pg/mg) patients are compared.